We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+109.07%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$510M
AUM Growth
+$233M
Cap. Flow
+$45.1M
Cap. Flow %
8.85%
Top 10 Hldgs %
42.94%
Holding
56
New
7
Increased
29
Reduced
8
Closed
9
Avg Time Held
5 quarters
Top 10 Avg Time Held
2.1 quarters
Top 20 Avg Time Held
4.3 quarters

Top Buys

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$9.74M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.11M
3
FOCL icon
EDAP TMS S.A.
FOCL
+$6.97M
4
FLXN icon
Flexion Therapeutics, Inc.
FLXN
+$5.24M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.4M

Top Sells

Rank Stock Value
1
TVRD icon
Tvardi Therapeutics
TVRD
+$8.04M
2
CYTK icon
Cytokinetics
CYTK
+$7.4M
3
SWAV icon
Shockwave Medical, Inc. Common Stock
SWAV
+$4.79M
4
THOR icon
Synthorx, Inc. Common Stock
THOR
+$2.93M
5
NXTC icon
NextCure
NXTC
+$2.62M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EPZM
1
DELISTED
Epizyme, Inc
EPZM
$34.1M 6.68%
1,384,200
+19,200
+1% +$285K
2018 Q1
7 quarters
APTO
2
DELISTED
Aptose Biosciences, Inc.
APTO
$23.2M 4.54%
9,078
+7,478
+467% +$9.74M
2019 Q3
1 quarter
CDXS icon
3
Codexis
CDXS
$151M
$22.3M 4.37%
1,400,000
+50,000
+4% +$740K
2014 Q1
23 quarters
FTSV
4
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$22.1M 4.34%
562,000
+137,000
+32% +$2.2M
2019 Q3
1 quarter
STXS icon
5
Stereotaxis
STXS
$109M
$22M 4.32%
4,112,500
+42,500
+1% +$169K
2019 Q3
1 quarter
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$21.2M 4.16%
340,500
+53,000
+18% +$2.52M
2019 Q3
1 quarter
OCUL icon
7
Ocular Therapeutix
OCUL
$1.64B
$20.2M 3.96%
5,107,500
+2,332,500
+84% +$8.11M
2019 Q1
3 quarters
HROW icon
8
Harrow
HROW
$1.06B
$18.2M 3.57%
2,340,000
-30,000
-1% -$174K
2018 Q3
5 quarters
EIDX
9
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$18.1M 3.55%
315,550
+10,000
+3% +$495K
2018 Q4
4 quarters
BOLD icon
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$17.5M 3.43%
292,000
+7,000
+2% +$263K
2017 Q2
10 quarters
NGNE icon
11
Neurogene
NGNE
$466M
$17M 3.34%
69,065
+19,315
+39% +$1.92M
2019 Q3
1 quarter
QURE icon
12
uniQure
QURE
$1.46B
$15M 2.95%
210,000
+5,000
+2% +$275K
2019 Q1
3 quarters
AMRN icon
13
Amarin Corp
AMRN
$240M
$14.3M 2.8%
33,250
+1,000
+3% +$380K
2017 Q4
8 quarters
DCPH icon
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14M 2.74%
224,500
-5,500
-2% -$261K
2018 Q1
7 quarters
ITCI icon
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.9M 2.74%
406,600
+236,600
+139% +$2.84M
2019 Q3
1 quarter
CCXI icon
16
DELISTED
ChemoCentryx, Inc.
CCXI
$13.8M 2.72%
361,600
+161,600
+81% +$2.84M
2019 Q3
1 quarter
AXGN icon
17
Axogen
AXGN
$2.14B
$12.5M 2.46%
700,000
– –
2015 Q1
19 quarters
AVTX icon
18
Avalo Therapeutics
AVTX
$679M
$11.8M 2.32%
761
+2
+0.3% +$21.1K
2018 Q4
4 quarters
ODT
19
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$11.5M 2.26%
355,000
+5,000
+1% +$155K
2018 Q4
4 quarters
ETON icon
20
Eton Pharmaceutcials
ETON
$1.55B
$10.6M 2.08%
1,469,456
+304,456
+26% +$1.88M
2018 Q4
4 quarters
XOMA icon
21
DELISTED
Xoma
XOMA
$10.2M 2%
373,450
-1,550
-0.4% -$34.7K
2017 Q1
11 quarters
ATXI icon
22
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$9.94M 1.95%
920
+73
+9% +$510K
2018 Q4
4 quarters
PTCT icon
23
PTC Therapeutics
PTCT
$5.06B
$9.17M 1.8%
191,000
+1,000
+0.5% +$42.5K
2018 Q1
7 quarters
BHVN icon
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.98M 1.76%
165,000
+5,000
+3% +$248K
2019 Q2
2 quarters
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$3.22B
$8.83M 1.73%
206,500
+6,500
+3% +$283K
2018 Q3
5 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2019 Portfolio in Review

As of Q4 2019, Opaleye Management held 56 positions worth $510M, up 84% from $277M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management deployed $45.1M of net new capital in Q4 2019, opening 7 new positions and adding to 29 existing holdings. Its largest new stake was Achillion Pharmaceuticals: 760,000 shares worth $4.58M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Quanterix, an estimated $1.2M trimmed.

  • Opaleye Management's largest Q4 2019 buy was Achillion Pharmaceuticals: 760,000 shares worth $4.58M.
  • Opaleye Management added most to Aptose Biosciences, Inc. in Q4 2019, an estimated $9.74M increase.
  • Opaleye Management's biggest Q4 2019 reduction was Quanterix, cutting an estimated $1.2M.
  • Opaleye Management fully exited Tvardi Therapeutics in Q4 2019, selling an estimated $8.04M.
  • Opaleye Management's ten largest holdings make up 43% of its $510M portfolio in Q4 2019.
  • Opaleye Management opened 7 new positions and closed 9 in Q4 2019.
  • Opaleye Management's portfolio value rose 84% quarter-over-quarter to $510M.

Based on Opaleye Management's 13F filing for Q4 2019, filed 14 Feb 2020.